Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
Hum Gene Ther. 2010 Jun;21(6):704-12. doi: 10.1089/hum.2009.182.
Hum Gene Ther. 2010.
PMID: 20095819